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Summary.-The study group included 684 cases: 258 patients with breast carcinoma,
113 males with lung cancer, 42 patients with rectal tumours, 42 patients with stomach
tumours, 59 patients with fibroadenomatosis, and 170 healthy subjects of varying age
(male and female).
A relatively high blood triglyceride level was found in patients with breast, lung,
rectal (females), and stomach (female) tumours. The blood concentration of high-
density lipoprotein-cholesterol in patients with breast, lung, and stomach (female)
tumours was relatively low. The elimination of tumour (breast carcinoma) did not
lead to significant changes in lipid metabolism. There was no correlation between
degree of lipidaemia and stage of tumour progression except in the cases of rectal
cancer.
Preliminary results are presented on the tentative classification of hyperlipo-
proteinaemia in tumour patients, using the lipid concentration threshold values
advocated by Carlson et al. (1977); an increased frequency of Type IV hyperlipo-
proteinaemia proved to be the most characteristic feature of tumour patients. The
results are discussed in terms of the concept of the importance of lipid metabolic
disturbances, primarily those due to ageing, in the genesis of the syndrome of
"cancerophilia" (predisposition to cancer).
DISTURBANCES OF LIPID METABOLISM
are a common feature of cancer patients
(Begg, 1958). Proper evaluation of these
disturbances is of major importance for
elucidation oftheir origin, for the appraisal
oftheir effects on the course ofthe tumour
process, and finally for making decisions
as to the advisability and type of correc-
tive measures to be taken.
There are 2 principal approaches to
the problem of the origin of metabolic
disturbances in tumour patients. On the
one hand, these disturbances may be the
result ofintensified transport of lipids and
carbohydrates to the tumour caused by the
influence of the tumour itself (Begg, 1958;
Kavetsky, 1962; Shapot, 1975). Although
this mechanism may well operate, es-
pecially in the later stages of tumour
progression, a number of data and con-
siderations point to other possible reasons
for disturbances of lipid metabolism, such
as nonspecific changes in the energy
homoeostat which are not dependent
upon the presence of a tumour and occur
in the course of normal ageing, especially
in some age-related diseases (Dilman,
1968, 1978a, 1979; Dilman et al., 1979).
These changes may be risk-factors for
tumour diseases and may be controllable.
Since it is known that the blood lipids
are components of circulating lipopro-
teins* which transport lipids (Eisenberg
& Levy, 1975), the lipid metabolism of an
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organism should be studied and discussed
in terms of lipoproteins. This was done in
detail by Barclay et al. (1970) and Barclay
& Skipsky (1975). Their finding that the
level of HDL is notably decreased in
tumour patients, and also in healthy sub-
jects from families with a positive cancer
history, lends support to the validity of
such an approach. But classical methods
of lipoprotein analysis require prolonged
ultracentrifugation, are time-consuming
and not available for most clinical labora-
tories. Therefore it seems important to
evaluate some simplified approaches based
on metal-polyanion precipitation (Bur-
stein & Scholnick, 1973) and on calcula-
tions using data on total triglyceride and
cholesterol content in blood. In contrast to
studies of hypercholesterolaemia in cancer
patients (e.g. Dilman & Bobrov, 1966;
Feldman & Carter, 1971; Smethurst et al.,
1975), disturbances of triglyceride content
in the blood of tumour patients have not
received sufficient attention. Furthermore,
there are no published data on attempts to
type hyperlipoproteinaemia in tumour
patients.
The aim of this paper is to present data
on the levels of triglycerides, cholesterol
and HDL-cholesterol in the blood of
patients with breast, lung, stomach, and
colonic tumours. An attempt will be made
to specify the hyperlipoproteinaemia
characteristic ofoncological patients.
Some data on lipidaemia in patients
with different neoplasms, mainly on the
level of cholesterol and free fatty acids in
bloodhave beenpublishedinearlierreports
from this laboratory (Dilman & Bobrov,
1966; Dilman et al., 1968; Tsyrlina et al.,
1977; Berstein et al., 1978).
MATERIALS AND METHODS
A total of 684 patients were examined: 258
breast-cancer patients aged 28-69; 113 males
with lung cancer (aged 31-70); 42 cases of
rectal cancer (18 males and 24 females, aged
37-69); 42 cases of stomach carcinoma (22
males and 20 females, aged 32-68); 59
patients wtith breast fibroadenomas (aged
23-69) and 170 healthy subjects (90 aged
20-29-45 male and 45 female, and 80 aged
>45 35 male and 45 female). The group of
breast-cancer patients included 185 cases of
primary tumour and 73 in clinical remission
(radical mastectomy followed by radiation
and/or cytostatic drugs, not less than 12
months before examination). For the other
sites, only patients with primarytumours were
examined. Most of the tumour patients were
in Clinical Stages II (a, b) and 111 (a, b), i.e.
wAithout clinical manifestations of distant
metastasis. Blood cholesterol wNas assayed by
a modification of the Lieberman-Burchardt
reaction (King, 1947), triglycerides were
estimated according to the method of
Carlson (1963), total :-lipoproteins (VLDL+
LDL) according to that of Ledvina &
Coufalova (1960) and HDL-cholesterol was
measured after removal of VLDL and LDL
from the serum by precipitation wAith heparin
and manganese chloride (Burstein & Schol-
nick, 1973). Threshold values of lipid concen-
trations for typing hyperlipoproteinaenmia
wNere chosen according to the recommenda-
tions of Carlson et al. (1977). Cases with
cholesterol levels > 290 mg/100 ml and
triglycerides < 180 mg/100 ml were referred
to as Type Ila; cholesterol >290 mg/100 ml
and triglycerides > 180 mg/100 ml-Type
IIb, and cholesterol <290 mg/100 ml and
triglycerides > 180 mg/100 ml-Type IV.
The blood level of LDL-cholesterol (LDL-Ch)
was obtained from the relation:
/(Triglyceride.s\ Total Ch - +HDL-Ch)
5J
(Rifkind, 1970). The atherogenic index (Al)
was defined according to Klimov and co-
w%orkers as
Total Ch-HDL-Ch
HDL-Ch
(Suchkova et al., 1978). The triglyceride level
of VLDL (VLDL-TG) was found from
TG Total Ch HDL-Ch
5 8
(Golubev, 1981). The statistical treatment of
results, was on the basis of Student's t test.
RESULTS
The data presented in Table I show an
age-associated rise in the blood levels of
total cholesterol, triglycerides, and total
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TABLE I.-Blood-lipid levels (mean +s.e.) in tumourpatients and healthy controls
Group
Control
Female
Male
Breast cancert
A
B
C
Lung cancer
Cancer of rectum
Female
Male
Cancer ofstomach
Female
Male
Age
(years)
20-29
45-78
20-29
45-70
53 + 1
52+0-7
56+0-6
58+0-7
Total
cholesterol
n (mg/100 ml)
45
45
45
35
48
137
73
113
192 + 4
246 + 8
184+6
241+5
251 +7
242 + 3
261+ 6
214+4*
Total
,-lipoproteins
Triglycerides (units of
(mg/100 ml) extinction)
88+6
103+6
109 + 4
139 + 9
156+ 10*
165+7* (58)t
161 + 6* (69)
163+6* (77)
388 + 14
459 + 20
382 + 17
538 + 24
586 + 15*
654 + 16* (75)
574+20* (63)
552+ 12 (59)
56 + 2 24 243 + 6 149 +11* (23) 580+ 21*
55 + 2 8 253 + 8 152 + 12 566 + 29
52 + 2 20 255 + 15 152 + 15* 581 + 29*
52+2 22 227+9 138+8 (21) 542+28
* Difference from age- and sex-matched controls is statistically significant (P < 0 05).
t Subgroup A-patients with primary tumours in whom blood level of HDL-cholesterol was determined;
Subgroup B primary patients in whom this parameter was not determined; Subgroup C patients in
remission.
t Figures in parentheses denote the number of cases, where this differs from the total.
P-lipoproteins in healthy males and fe-
males. The blood concentrations of tri-
glycerides and total /-lipoproteins in the
older group of healthy males were sig-
nificantly higher than in corresponding
group of healthy females (P < 0 05) whilst
HDL-cholesterol levels were lower (P <
0.1). The tumour patients (except males
with stomach and rectal tumours) revealed
a significantly raised content of tri-
glycerides and total /B-lipoproteins as com-
pared with healthy controls of the same
age. In contrast, HDL-cholesterol levels in
patients with primary breast, lung, and
stomach (females) tumours proved to be
significantly lower than in healthy con-
trols of the same sex. The serum total
cholesterol concentration in lung-cancer
patients was lower than in the healthy
males of the older age group; for tumours
at other sites it did not show significant
differences from age-matched controls.
This parameter in breast cancer patients
was significantly higher (P < 0 05) than in
those with fibroadenomatosis, in whom
blood cholesterol levels were 217 + 6 (whole
group, n=59) and 228+10mg/lOOml
(patients over 50 years, n =22) respec-
tively. It should be stressed that no sig-
nificant differences in the indices of lipi-
daemia between primary-breast-cancer
patients and those in clinical remission
were found (Table I).
It is evident from Table II that the
clinical stage oftumour progression had no
definite effect on blood-lipid levels (except
rectal-cancer patients). VLDL-triglyceride
concentration was significantly higher
than in controls (Table III). There were no
significant differences in the atherogenic
index, HDL-cholesterol:total-cholesterol
ratio or the LDL-cholesterol concentration
in the blood of tumour patients and con-
trols.
The incidence of hyperlipoproteinaemia
in healthy controls was lower than in
tumour patients (Table IV). Type Ila was
more frequent in female controls, and
Type IV in males. The latter phenomenon
appeared to be more pronounced in male
patients with lung cancer, unlike those
suffering from rectal andstomachtumours,
in whom Type Ila hyperlipoproteinaemia
was asfrequent asType IV. A considerably
increased incidence of Type IV hyper-
lipoproteinaemia, and a decreased inci-
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cholesterol
(mg/10O ml)
59+2 (28)
53+3 (14)
51 + 1*
57 + 3 (21)
45+2* (15)
56+3 (14)
48+3-5 (12)
51 + 3* (9)
49+3-5 (13)640 V. M. DILMAN ET AL.
TABLE II.-Blood-lipid levels (mean +s.e.) in relation to stage ofmalignant disease
Total
Total ,-lipoproteins HDL-
cholesterol Triglycerides (units of cholesterol
Group Stage n (mg/100 ml) (mg/100 ml) extinction) (mg/100 ml)
Breastcancert I 11 252+17 151+12 557+37 53+3
II 11 259+15 179+15 618 + 29 51+ 3
III 22 247+11 153+17 578+18 51+ 2
Lung cancer I-II 23 210+ 9 171+18 533 + 33
III 28 220+ 9 122 +9* 548 + 29
IV 11 221 + 6 161+ 20 481+ 21
Cancer of rectum I-II 6 286 + 10 171+ 33 670 + 26 57+ 6
III 18 243 + 8 157+13 556 + 21* 51+ 3
IV 9 233+11* 119+16 505+23* 54+8
Cancer ofstomach I-II 9 228 + 14 128 + 17 557 + 32 50+ 3
III 20 245 + 12 147 +12 558 + 31 54+ 4
IV 10 216+23 157+22 519+57 51+3
*Difference from data in patients in Stage I-II is statistically significant.
t Subgroup A in Table I.
TABLE III.-Some calculated indices of lipidaemia in tumour patients
Group HDL-Ch/Ch LDL-Ch VLDL-TG Al
Control (> 45 yr) Female 0-22 + 0 01 176+10 71+ 6 3-62 + 0 19
Male 0-23+0-02 158+6 76+ 17 3-65+0-31
Breast cancer Subgr. A 0-21+ 0-01 169 + 5 118+7* 4-08 + 0-16
Subgr. C 0-21+0-01 196+9 85+9 4-16+0-31
Lung cancer 0-20+ 0 01 147 + 9 135 + 12* 4-42 + 0 34
Cancer ofrectum Female 0-24 + 0-02 156 + 9 109 + 12* 3 40 + 0-29
Male 0-19+0-01 169+8 109+15 4-31+0-29
Cancer ofstomach Female 0-23 + 0-02 149 + 11 129 + 14* 3-68 +0(37
Male 0-22+0-01 146+9 106+8 3-97+0-42
* Difference from sex-matched controls is statistically significant (P < 0 05).
t See Materials and Methods.
TABLE IV.-Incidence ofdifferent types ofhyperlipoproteinaemia (%) in tumour patients
and healthy controls (based on criteria of Carlson et al., 1977)
Types ofhyperlip3proteina-rnia
(0/)
K ~~~~~~~~A
Group Ila lIb IV Normal
Control (> 45 yr) F 18 7 0 3 1 78 2
M 57 0 114 829
Breast cancer A 7 5 11b7 20-2 60 6
C 21-3 9.3 20.0 49-4
Lung cancer 1-3 1-3 24-7 72 7
Cancer ofrectum F 4-3 8-6 17-2 69-9
M 16-7 0 22-2 61-1
Cancer ofstomach F 11-1 16-7 11-1 61-1
M 14-3 0 19-0 66-7HYPERLIPIDAEMIA IN CANCER
dence of Type hIa (primary breast cancer
and rectal cancer), when compared with
healthy females, proved to be typical of
female tumour patients.
1)ISCUSSION
The importance of studying lipid meta-
bolism in tumour patients follows from
data on the role of cholesterol in cell
proliferation (H. W. Chen et al., 1977), on
the inhibitory effects of disturbances of
carbohydrate-lipid metabolism on the
immune system (Dilman, 1977, 1978b), on
the immunosuppressive effects of some
particular lipids, like polyunsaturated
fatty acids (Meade & Mertin, 1978), on
the possibility of influencing tumour
growth by changes in lipid metabolism
(Littman et al., 1966).
Questions concerning lipid metabolism
cannot be discussed without taking into
consideration the fact that the blood lipids
are components ofcirculating lipoproteins.
Data on the total cholesterol and triglycer-
ide and on HDL-cholesterol content of
blood of tumour patients, presented in
Table I, allow one to draw some conclu-
sions about lipoprotein concentration,
after appropriate calculations (see
Methods) have been made. It should
be mentioned that any calculations of this
kind are valid provided there are no sig-
nificant differences in lipoprotein composi-
tion between controls and cancer patients.
We found no evidence in the literature
for such differences. The data in Table III
suggest that the main reason for the
apparent changes of cholesterol and tri-
glyceride concentrations in the blood ofthe
patients examined is the rise ofVLDL, the
triglyceride carrier. This appears to be the
cause ofthe rise ofg-lipoproteins intumour
patients observed by other investigators
(Nanava & Tzinzadze, 1961; Miller & Erf,
1956) as well as in the present study. The
concentration ofHDL in the blood of some
groups of tumour patients, on the other
hand, is reduced as assessed by HDL-
cholesterol concentration (Table I).
As to the results of typing of hyper-
lipidaemia, it should be mentioned first
that dealing with oncological patients, we
exclude those rare primary disorders of
lipid metabolism that were the basis for
the original concept of different types of
hyperlipidaemia. What we are dealing
with here should be regarded rather as
phenocopies of the corresponding types
of hyperlipidaemia.
The prevalence of Type IV hyperlipo-
proteinaemia in cancer patients (Table
IV) might be due to a reduced rate of
fractional turnover of VLDL (i.e. of tri-
glycerides), which is common in moderate
Type IV hyperlipoproteinaemia (Havel
et al., 1970; Quarfordt et al., 1970;
Olefsky et al., 1974; Rossner et al., 1976)
or due to enhanced synthesis of tri-
glycerides. The observation that the
concentrations of triglyceride and other
lipids in the blood of tumour patients do
not depend upon the stage of the disease
(Table II) militates against the concept
that the tumour itself plays the primary
role in the disturbances of lipid metabo-
lism (Begg, 1958; Liebelt et al., 1971) and
does not support the idea that a steady
decrease in blood lipid concentrations
during tumour progression reflects the
dubious prognosis for the patients (Rose
et al., 1974; Chao etal., 1975).
Another argument against the primary
role of the tumour in disturbing the lipid
metabolism of tumour patients is the
persistence of hyperlipidaemia in breast-
cancer patients for months and even years
after radical mastectomy (Table I). The
above evidence suggests that high blood
lipid levels in tumour patients reflects a
higher risk for subjects with hyperlipid-
aemia of developing tumours, rather than
the presence of a tumour. This conclusion
is supported by the findings of Barclay &
Skipsky (1975) that the level of HDL is
diminished and of VLDL is raised not
only in cancer patients, but also in healthy
subjects from families with a cancer
history. Besides, the VLDL andLDLlevels
rise in the course of normal ageing (see
Table I) as a result of the primary hypo-
thalamic shifts. This point is discussed in
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detail in Dilman (1968, 1979, 1980) and
Dilman et al. (1979). It should be stressed
that from this point ofview only the levels
of lipids and other metabolites character-
istic for the ages of 20-25 years, when
cancer incidence is lowest, may be con-
sidered as normal, so even when there is no
difference in blood lipids between cancer
patients and age-matched controls, the
patients should be regarded as hyper-
lipidaemic compared with healthy persons
aged 20-25 (Dilman, 1979, 1980).
Such an approach treats metabolic
disorders which are characteristic of can-
cer as components of the syndrome of
cancerophilia. This term needs comment.
The concept of predisposition to cancer is
widespread. But anyone using it has his
own opinion of what it should mean. In
our opinion no matter what the immediate
causes of malignant transformation, there
are 3 main factors promoting this process:
(1) enhanced cell proliferation; (2) reduced
cellular immunity; and (3) reduced DNA
repair. There is evidence that hyper-
lipidaemia ofthe type that develops in the
course of normal ageing (characterized by
lowered glucose tolerance, by reactive
hyperinsulinaemia and by other related
metabolic disturbances) may promote all
3 of them. For example, hyperlipidaemic
serum enhances cell proliferation (R. M.
Chen et al., 1977). Hyperlipidaemia causes
metabolic immunodepression (Dilman,
1977, 1978a,b). Preliminary data from our
laboratory demonstrate a negative corre-
lation between the cholesterol content of
blood and lymphocytes on the one hand,
and the rate of DNA repair on the other.
The complex of metabolic disorders that
promotes the development of the above 3
conditions favourable for tumour progres-
sion has been designated as cancerophilia
(Dilman, 1977, 1978a,b). This complex
must include not only metabolic but also
related hormonal shifts. In particular,
hyperinsulinaemia, often connected with
hypertriglyceridaemia, should be men-
tioned as a factor promoting cell prolifera-
tion.
It should be borne in mind that the
systemic effects of a tumour (Shapot,
1975) may further aggravate metabolic
disorders that served as a risk factor for
the appearance ofthe tumour, and so may
cause secondary cancerophilia. The evi-
dence presented in this paper suggests the
possibility of using dietary and pharmaco-
logical means ofcorrection oflipid metabo-
lism in cancer prophylaxis and therapy.
The evaluation of such treatment of can-
cer is under investigation.
In a recent editorial in The Lancet (1980)
it was stated that a lowered cholesterol
level predisposes to cancer. The depen-
dence of cancer incidence upon blood
cholesterol may be rather complicated.
The data of Rose & Shipley (1980) show
a connection between lowered blood
cholesterol and the appearance of colonic
cancer 2 years later. When the interval
between examination of blood cholesterol
and the appearance of a tumour was more
than 2 years, there was a positive corre-
lation between blood cholesterol level and
cancer incidence. In the former case the
lowered cholesterol level could be a result
of systemic effects of the tumour which
does not manifest itself clinically. In the
latter case high cholesterol level could be a
true risk factor for tumour development.
Besides this, the data of Westlung &
Nicolaysen (1972) showed that extremely
high levels of blood cholesterol may be
connected with a lower cancer incidence.
There may be special reasons (e.g. genetic
disorders) for these high levels which may
beunrelated tolipidabnormalities foundin
cancerophilia.
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